Vinod Pullarkat, MD
Hematology · Duarte, CANPI 1164433645
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 19.9%. Among hematology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 557 payments — averaging $1033.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$115K
- AbbVie$88K
- AstraZeneca$74K
- Jazz Pharmaceuticals Inc.$74K
- Amgen$45K
- Sobi, Inc$35K
- plus $145K from 26 others
Across 394 payments — averaging $23,859 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3.4M
- Jazz Pharmaceuticals Inc.$2.4M
- AbbVie$2.1M
- Servier Bioinnovation$1.3M
- Institut DE Recherches Servier$97K
- Sanofi$30K
- plus $31K from 3 others
What the payments were for
- Consulting fees$218,51638%
- Speaking & faculty fees$295,96451%
- Travel & lodging$42,5877%
- Food & beverage$18,3283%
- Education$2970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 105 | $114,559 |
| AbbVie | 98 | $88,015 |
| AstraZeneca(2 entities) | 63 | $74,236 |
| Jazz Pharmaceuticals Inc. | 62 | $73,939 |
| Amgen | 57 | $44,891 |
| Sobi, Inc | 19 | $34,719 |
| Servier Pharmaceuticals LLC | 36 | $30,604 |
| Dova Pharmaceuticals | 12 | $20,547 |
| Sanofi | 10 | $20,015 |
| Rigel Pharmaceuticals, Inc. | 20 | $17,726 |
| Bristol Myers Squibb | 12 | $11,298 |
| E.r. Squibb & Sons, L.L.C. | 5 | $9,607 |
| Acceleron Pharma, Inc. | 6 | $6,819 |
| Genentech USA, Inc. | 10 | $6,431 |
| Pfizer | 5 | $6,209 |
| Blueprint Medicines Corporation | 4 | $5,780 |
| Pharmacosmos Therapeutics Inc. | 3 | $2,943 |
| Argenx US, Inc. | 1 | $2,800 |
| Agios Pharmaceuticals, Inc. | 1 | $2,800 |
| Gilead | 5 | $488 |
| Syndax Pharmaceuticals, Inc. | 1 | $214 |
| Incyte Corporation | 5 | $192 |
| Beone Medicines USA, Inc. | 2 | $180 |
| Astellas Pharma US Inc | 1 | $154 |
| Seagen Inc. | 2 | $114 |
| Biocryst US Sales Co., LLC | 1 | $103 |
| Daiichi Sankyo Inc. | 4 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Merck | 3 | $61 |
| Johnson & Johnson | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$575,691 in reported general payments places this provider in the 95th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 80 | $1,352,330 |
| IclusigPonatinib Hcl | 16 | $347,493 |
| DopteletAvatrombopag Maleate | 17 | $227,245 |
| VenclextaVenetoclax | 15 | $153,726 |
| EliquisApixaban | 62 | $70,659 |
| XareltoRivaroxaban | 25 | $25,425 |
| Enoxaparin Sodium | 42 | $10,425 |
| Entecavir | 14 | $2,223 |
| Warfarin Sodium | 63 | $589 |
| Acyclovir | 35 | $476 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $192 | $1,352,33080 claims |
| Dova PharmaceuticalsDoptelet | $20,547 | $227,24517 claims |
| AbbVieVenclexta | $88,015 | $153,72615 claims |
| PfizerEliquis | $6,209 | $70,65962 claims |
| Johnson & JohnsonXarelto | $21 | $25,42525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 178 hematology providers in California.
Other hematology in Duarte
- Amrita KrishnanDuarte$671K
- Alexey DanilovDuarte$407K
- Tycel PhillipsDuarte$348K
- Haris AliDuarte$310K
- Amandeep SalhotraDuarte$214K
- Tanya SiddiqiDuarte$199K
- Scott GoldsmithDuarte$180K
- Ibrahim AldossDuarte$175K
- Alex HerreraDuarte$155K
- Geoffrey ShouseDuarte$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.